J&J’s Ottava Robot Cleared FDA. Beating da Vinci Is a Different Problem

Johnson & Johnson just put arguably the most differentiated surgical robot in years onto the US market. Its Ottava system cleared the FDA on Wednesday, it is smaller and more automated than the machine it is chasing, and the analysts who cover Intuitive still shrugged. One of them told clients it is unlikely to take meaningful share from da Vinci any time soon. That gap, between a genuinely better-built robot and a market that may not care yet, is the part worth understanding whether you sell robots, factory automation, or clinical software.

What J&J actually cleared

Johnson & Johnson received FDA De Novo authorization for Ottava in general surgery, covering procedures from Roux-en-Y gastric bypass and gastrectomy to cholecystectomy and appendectomy. It is the first soft-tissue system to build its robotic arms into the operating table rather than parking them on booms and carts, which is how it takes up 30 to 50 percent less room in the OR. J&J’s medtech chairman Tim Schmid called it a new category of surgical robotics, and the file cleared about six months after submission, fast for a De Novo, according to MedTech Dive. This is the second heavyweight to reach Intuitive’s turf in under a year, after Medtronic’s Hugo cleared for urology in late 2025. After more than two decades alone, da Vinci finally has company. None of this is a weak product.

Why the better robot might still lose the room

So why did J.P. Morgan’s analyst tell clients Ottava is unlikely to materially dent Intuitive’s share, and why did Stifel flag that the launch will be slow and training-heavy? Because Intuitive never defended its position on specifications. It defended on the surgeon’s hands. Twenty-five years of da Vinci means tens of thousands of surgeons whose muscle memory is wired to one console, hospitals with the systems bolted into their rooms and their instrument contracts, and residency programs that train the next generation on the same machine. Switching robots is not a purchasing decision. It is asking a skilled professional to relearn a task they perform under real consequence, and surgeons do not relearn their hands casually.

There is an irony sitting inside J&J’s boldest move. The table-integrated design is the most interesting thing about Ottava, and it is also its steepest adoption cost, because a genuinely new workflow is exactly what an entrenched surgeon resists. The moment a product asks people to retrain habits they built over years, it is fighting muscle memory, and muscle memory is the strongest lock the incumbent has.

The read for anyone selling into a trained workflow

This is not only a surgical robotics problem. If your product lives inside the workflow of a trained operator, whether that is a surgeon, a machinist, a field technician, or a clinician clicking through software forty times a day, the incumbent’s real defense is almost never its feature list. It is the cost of making a skilled user unlearn what their hands already know. You have two honest options. Fit the existing workflow closely enough that switching is nearly free, or accept that displacement will be slow and deliberate and fund it accordingly. What does not work is assuming a better spec sheet earns the switch. I watched this up close building a surgical robot. If the thing did not fit what surgeons already did with their hands, it did not solve their problem, it added one, no matter how good the engineering looked on paper.

Dave Saunders is the founder of Base Reality Group and a Fractional CPO for hard-tech founders. He was a founder and operator at Galen Robotics, where the surgical-robotics platform earned FDA De Novo authorization in 2023, and he managed a 35-patent portfolio licensed from Johns Hopkins. He wrote Founders Who Finish and publishes The Build. More about Dave →